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Intravenous infusion of arrhythmogenic drug solutions was used 
as a pharmacological tool to measure the ventricular fibrillation 
threshold. Reserpinized animals increased the fibrillation thresh­
old of McN2165. Animals reserpinized two weeks prior to the ex­
periment still demonstrated an increased fibrillation threshold. 
Pronethalol, norepinephine, phenoxybenzamine, and neostigmine all 
increased the fibrillation threshold of McN2165, while atropine 
produced no change. Isoproterenol was the only drug that lowered 
the threshold. Reserpinized animals pretreated with norepinephrine 
still demonstrated an increased fibrillation threshold. Isopro­
terenol decreased the threshold even when the animals were reser­
pinized. Pronethaloel was able to suspend the fibrillation induced 
by McN2165. Beta receptors appear to be involved in the induction 
ventricular fibrillation by McN2165.
Reserpine and pronethalol both increased the fibrillation thresh­
old of strophanthin K, while isoproterenol lowered the threshold. 
Pronethalol was not able to suspend the fibrillation induced by 
strophanthin K.
Reserpine, pronethalol, and isoproterenol all increased the fi­
brillation threshold of barium chloride and pronethalol could not 
suspend the fibrillation induced by it.
Normal administration of reserpine and isoproterenol did not 
change the threshold of aconitine. Pronethalol and intraperito- 
neal injection of reserpine increased the fibrillation threshold. 
Pronethalol was also unable to stop the fibrillation induced by 
aconitine. The arrhythmogenic action of McN2165 is different from 
any other arrhythmogenic agent used in this study.
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CHAPTER 1 
INTRODUCTION
The heart contains four chambers— two thin walled atria 
and two thicker-walled ventricles. The atria lie above the 
ventricles and are responsible for forcing the blood they 
receive into the ventricles. The ventricles do most of the 
work of the heart, expelling the blood into the circulation. 
In the mammalian heart the S.A. (sino-atrial) node located 
in the right atrium is the pacemaker (Keith and Flack, 1970). 
This region initiates a depolarizing current which spreads 
over the atria. The atrioventricular or A.V. bundle, begins 
with the A.V. (atrioventricular) node at the base of the 
atrial septum and passes along the upper edge of the ventri­
cular septum. The A.V. bundle then divides into two branches 
which run down each side of the ventricular septum to the 
right and the left ventricles. Each branch forms a reticu­
lated layer under the endocardium of the ventricles, called 
Purkinje tissue. The excitatory process is transmitted 
from the S.A. node to the A.V. node and then through the A.V. 
bundle to the Purkinje tissue. The wave of excitation allows 
calcium to reach the myofibrils and initiate contraction 
(Brody, 1964). In this way, the two atria can contract
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almost simultaneously and empty the blood into the two ven­
tricles. The ventricles then contract and expel the blood 
into the circulation.
Cardiac output, the amount of the blood expelled per 
heart beat, depends on the heart rate and stroke volume. 
Cardiac output is regulated by the autonomic nervous system 
and by venous return. The sympathetic branch of the autonomic 
nervous system contains the accelerator fibers that go to the 
heart. Those in the right outflow are distributed mainly to 
the S.A. node, and those from the left outflow supply the 
A.V. node. Stimulation of these accelerator nerves causes 
the release of catecholamines, which in turn cause an in­
crease in rate (chronotropism) and force of contraction (ino- 
tropism), This applies both to the atria and to the ventri­
cles. Randall (1956) showed that the right and left cardiac 
sympathetic innervation are different in many respests. The 
right and left stellate ganglia have predominantly chronotro­
pic and inotropic effects respectively and the right and left 
stellate ganglia have opposite effects on the T wave of the 
electrocardiogram (Yanowitz, 1966).
The other part of the autonomic nervous system is the 
parasympathetic nervous system. The vagus nerves are cardio- 
inhibitory, conveying impulses from the cardioinhibitory 
center in the medulla to the S.A. node and A.V. node of the 
heart. Both S.A. node and A.V. node are influenced by the 
autonomic nerves (Urthaler, et al, 1973). Stimulation of
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vagus nerve slows the heart rate (negative chronotropism) and 
the conductivity of the atria to the ventricles (negative 
dromotropism). Strong stimulation of the vagus can completely 
stop the rhythmic contraction of the S.A. node or completely 
block the transmission of the cardiac impulse through the A.V. 
junction. The parasympathetic nervous system dominates the
S.A. node while the sympathetic dominates the A.V. node (Bell, 
et a l , 19 7 0) .
Cardiac output is a function of Starling's Law which 
states that the force of contraction (systole) of the heart 
is related to the degree of stretching of the muscle prior 
to contraction. The heart also responds to the blood concen­
tration of catecholamines. These hormones are released by 
the adrenal medulla upon stimulation by the autonomic nervous 
system. The central nervous system also plays an important 
role in controlling blood pressure and heart rate (Laubie,
1976).
The S.A. node controls the rate of the heart. The rate 
of depolarization of the S.A. node is considerably greater 
than that of any other region of cardiac tissue. Each time 
the S.A. node discharges, its impulse is conducted both into 
the A.V. node and into the Purkinje fibers, discharging their 
excitable membranes. Then all the tissues begin their cycle 
of recovery. But the S.A. node recovers much more rapidly 
than does any other part of the heart, and emits still anoth­
er impulse. Under pathological conditions, other areas of
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the heart develop a rhythmic discharge rate which is more 
rapid than that of the S.A. node. These parts can be the 
A.V. node, Purkinje fibers, or any points in the atrial or 
ventricular muscle. These additional pacemakers are called 
ectopic foci. An ectopic pacemaker causes an abnormal se­
quence of contractions.
Abnormal cardiac rhythms can be caused by ;
1. Abnormal rhythmicity of the pacemaker itself.
2. Shift of the pacemaker from the S.A. node to other parts 
of the heart.
3. Blocks at different points in the transmission of the 
impulse through the heart, usually from a myocardial 
infarction.
4. Abnormal pathways of impulse transmission through the 
heart, and
5. Spontaneous generation of abnormal impulses in almost 
any part of the heart.
In any general discussion of the initiation of cardiac
arrhythmias, the relative merits of the ectopic focus and 
reentrant theories, is bound to arise.
Segers {Dawes, 1952) first described the possibility of 
an ectopic focus as the origin of arrhythmias. The ectopic 
focus is not limited to one single cell. It can be a small
group of cells sending rapid impulses in all directions.
This results in rapid rates of contraction, leading to 
tachycardia, flutter and even fibrillation.
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The reentrant activity theory consists of two elements; 
the circus movement and the focal reexcitation. McWilliam 
(190 8) first described the possibility of circus movement as 
the underlying mechanism of cardiac arrhythmias. It is due 
to propagation of the impulse in a circular path. A funda­
mental requirement for such a circus movement is an area of 
refractory tissue which initially fails to respond to an im­
pulse propagating in one direction. This is due to the 
presence of a unidirectional block. Because this area then 
recovers its excitability, it accepts reentry of the same 
impulse when it returns in the opposite direction. Such a 
continuous circus movement will be possible only if an excit­
able area of tissue always exists in front of the excitation 
process. Mauritis and co-workers (1973) demonstrated the 
circus movement as a mechanism of tachycardia in rabbit 
atrial muscle preparation. The other type of reentrant ac­
tivity is the focal reexcitation. It is not associated with 
a circus movement loop. It may occur if there is a disparate 
rate of repolarization in neighboring myocardial fibers, so 
that fibers already repolarized are reexcited by fibers still 
depolarized. The potential difference of the depolarized 
fibers exceeds the threshold potential of the repolarized 
fibers. This would result in closely coupled ventricular 
ectopic beats. Reexcitation of this type may generate rapid, 
repetitive responses in the ventricle. Han and co-workers 
(196 4) demonstrated that focal reexcitation may occur follow­
ing coronary occlusion.
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Ventricular fibrillation is a major cause of sudden 
deaths from heart diseases. Evidence indicates that cat­
echolamines may be involved in the genesis of the early ven­
tricular arrhythmias that accompany an acute myocardial 
infarction. In 1911 Levy showed that epinephrine could 
induce ventricular fibrillation in cats under chloroform 
anaesthesia. Raines and co-workers (1970) showed that di- 
phenylhydantoin increased the fibrillation threshold of 
ouabain-induced ventricular arrhythmias by suppression of 
the sympathetic influence. The use of beta receptor blocker 
seemed to both prevent and cure the fibrillation precipitated 
by cardiac glycosides (Vaughn Williams, et al, 1963). It was 
found that catecholamines secreted by the sympathetic ganglia 
have several biochemical effects on cardiac muscle. These 
hormones stimulate the formation of cyclic 3'5* adenosine 
monophosphate by the enzyme adenyl cyclase (13. W. Sutherland, 
et ai, 1961). The cyclic AMP serves as a "second messenger" 
to initiate lipolysis, glycogenolysis and inhibition of gly­
cogen synthesis. High cyclic AMP levels in myocardial muscle 
have positive inotropic effects on the heart (Burthon, 1973). 
It has been suggested that catecholamines increase the con­
centration of cyclic AMP which in turn acts at the sarco­
plasmic reticulum to accelerate the inflow of calcium ions 
and cause the positive inotropic effect. Further studies 
showed that cyclic AMP concentration was increased during 
ventricular fibrillation caused by ischaemic heart disease 
or a myocardial infarction (Wollenberger et al, 1969).
Reproduced with permission of the copyright owner. Further reproduction prohibited without permission.
7
Tsien and co-worker (1972) found that cyclic AMP in­
creased the pacemaker activity in normal Purkinje fibers in 
the heart. This indicated that increases in cyclic AMP 
level might lead to repetitive excitation in the partially 
depolarized, ischaemic heart muscle. Further evidence showed 
that the higher cyclic AMP level produced by catecholamines 
decreased the ventricular fibrillation threshold in isolated 
rat hearts (Lubbe, et a i , 1976). It is possible that the 
ventricular fibrillation produced by catecholamines is due 
to elevated cyclic AMP levels in the myocardial tissue 
(Murad, et al, 1961).
There are several techniques employed to study the 
mechanism by which an arrhythmogenic drug induces cardiac 
arrhythmias. The isolated heart preparation has been widely 
used (Stafford, 196 3). Another preparation is the heart-lung 
preparation. This technique was first used by Krayer in 1931 
(Burn, et al, 1958). The use of the whole animal to measure 
the fibrillation dose or fibrillation threshold of barium 
chloride was employed by Smith et al, (1940). Since then, 
intravenous infusion of arrhythmogenic substances to measure 
the fibrillation threshold has become one of the classic ex­
periments to measure the efficacy of antiarrhythmic agents. 
Also, other drugs were employed in the whole animal prepara­
tion to pharmacologically modify the fibrillation threshold.
A disadvantage of this preparation is that a given drug may 
have multiple effects on the organism. The advantage of
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using this preparation in this research is that the nervous 
system, hormonal secretion, and the physiological reflexes 
are all present.
Aconitine is a classic arrhythmogenic drug. Local 
application of aconitine to the atrial appendage, in the 
"intact" anesthetized dog produces atrial flutter and fibril­
lation (Sharma, 1963), Intravenous injection of aconitine 
nitrate solution can produce ventricular tachycardia and fi­
brillation. It is believed that these arrhythmias are due 
to the rapid discharge of an ectopic focus (Scherf, et al, 
1949) .
Barium chloride is an inorganic compound that has the 
effect of stimulation of all smooth muscles. Intravenous 
injection causes a sharp rise of blood pressure at the same 
time as extrasystoles occur. Barium causes depolarization 
and a considerable increase in the after potential. Suffi­
cient dose can cause ventricular fibrillation (Smith, et al, 
(1940).
Storphanthin K, one of the cardiac glycosides, has the 
ability to increase the force of myocardial contraction. 
Cardiac glycosides have been shown to inhibit a sodium and 
potassium-stimulated adenosine triphosphatase (ATPase). In 
sufficiently high dose, cardiac glycosides may precipitate 
arrhythmias, including ventricular fibrillation (Sekiya, 
et a l , 1963).
McN2165 is an experimental compound that can produce 
ventricular arrhythmias. It has the effect of increasing
Reproduced with permission of the copyright owner. Further reproduction prohibited without permission.
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the QRS interval and cyclic AMP level (Pryss, 1969; Eyer and 
Johnson, 1977). The terminal effects of the compound in 
anesthetized rat included ventricular tachycardia, ventricu­
lar flutter, ventricular fibrillation, and death. The 
mechanism of induction of ventricular fibrillation by this 
agent has not been determined. In order to determine the 
role of the autonomic nervous system in the cardiac arrhyth­
mias caused by McN2162, the following autonomic agents were 
used ;
Reserpine is an alkaloid found in extracts of R a u w o l fia 
serpentina. In the central nervous system reserpine depletes 
serotonin and norepinephrine from neurons. Other peripheral 
neurons as well as the adrenal medulla are also depleted.
The catecholamine uptake mechanism is also antagonized (Matti, 
et al, 1958). Initially, the responses to indirect acting 
sympathomimetic amines are potentiated, but later are absent. 
The effects of reserpine remain for several weeks.
Neostigmine is an anticholinesterase. This drug binds 
to cholinesterase and is hydrolyzed extremely slowly. Neo­
stigmine has a direct depolarizing action on the neuromuscu­
lar junction. The predominant effects on the heart will be 
bradycardia due to enhanced vagus nerve influence on the S.A. 
node.
The antagonist to neostigmine is atropine. Atropine 
competitively antagonizes the action of cholinergic drugs 
at the muscarinic receptors. It increases the heart rate by 
blocking the effects of vagus nerve on the S.A. node.
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Phenoxybenzamine is a selective alpha adrenergic blocker, 
totally without effects on the beta responses. It is a very 
potent irreversible blocker of norepinephrine. Therefore, 
this drug potentiates the beta action of norepinephrine. 
Phenoxybenzamine reflexively increases the heart rate because 
of its vasodilating action {Moran, et al, 1962).
Pronethalol is a beta adrenergic blocker. This drug is 
a potent blocker of catecholamine action on the heart, and 
also has a depressant action on adrenergic nerves, (Standaert, 
et al, 1967).
Norepinephrine is the postganglionic neurotransmitter 
of the sympathetic nervous system. It is more active on 
alpha receptors than on beta receptors, but is by no means 
devoid of beta activity. Norepinephrine increases heart rate 
and blood pressure. A sufficiently high dose can cause car­
diac arrhythmias.
The actions of isoproterenol are exerted almost entirely 
on the beta receptors. This drug produces strong positive 
intropic and chronotropic actions on the heart. Isoproter­
enol stimulates adenyl cyclase and is about ten times as 
potent as either epinephrine or 1-norepinephrine (Sutherland, 
et al, 1960).
The effects of these autonomic agents on the arrhythmogenic 
action of McN2165 was also compared with their action on the 
other arrhythmogenic agents.
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CHAPTER 2 
MATERIALS AND METHODS
Methods
Male Sprague-Dawley rats (350-400 grams) were used for 
all the experiments. Animals were anesthetized with sodim 
pentobarbital (30-35 mg/kg i.p.), supplemented by additional 
doses as needed. The rats were connected to a physiograph 
from Narco Bio Systems, Inc. The lead II electrocardiograms 
(EKG) were recorded continuously with an ink-writing Oscillo­
graph (paper speed 5 cm/sec) and monitored on a type 502 
Dual-Beam Oscilloscope. McN216 5, aconitine, barium chloride, 
and strophanthin K were administered through the femoral vein 
by means of an infusion syringe pump (Model 255-2 Sage Instru­
ments) until ventricular fibrillation occurred. The rate on 
constant infusion of the arrhythmogenic agents was 1.80 mg/ 
kg/min for McN2165, 4.32 mg/kg/min for barium chloride, 0,014 
mg/kg/min for aconitine nitrate, and 2.7 mg/kg/min for stro­
phanthin K. The infusion was discontinued as soon as the 
ventricular fibrillation started, A timer was used to time 
the onset of ventricular fibrillation.
A separate series of experiments, the animals were in­
fused to the point of ventricular fibrillation by the
11
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arrhythmogenic agents. As soon as the heart started to fi- 
brillate, pronethalol 5 mg/kg was given intravenously to see 
if the fibrillation could be suspended.
Preparation and Administration of Drugs
These arrhythmogenic agents are prepared as follows :
Because of its low water solubility, McN216 5 (McNeil 
Laboratories, Inc.) was dissolved in 75% alcohol and 25% 
normal saline. This drug was agitated approximately 15 min­
utes until it all dissolved, yielding a solution of 10 mg/ml. 
Aconitine nitrate (S. B. Penick and Company), barium chloride 
(J. T. Baker Chemical Co.), and strophanthin K (Nutritional 
Biochemical Corporation) were dissolved in distilled water to 
give a solution of 0.5 mg/ml, 40 mg/ml, and 25 mg/ml respec­
tively.
Proenthalol (Ayerst Laboratories) neostigmine bromide 
(Hoffmann-LaRoche, Inc.) and atropine sulfate (Mallinckrodt 
Chemical Works) were dissolved in distilled water and admin­
istered rapidly via the femoral vein ten minutes prior to 
infusion of the arrhythmogenic agent.
L-Isoproterenol-D-Bitartrate (Sigma Chemical Co.) and 
norepinephrine (Levophed^ Bitartrate, Winthrop Laboratories, 
Inc.) were dissolved in distilled water and were given intra­
venously twenty seconds prior to the arrhythmogenic agents.
Phenoxybenzamine hydrochloride (Smith Kline and French 
Labs.) was dissolved in distilled water and given intraperi- 
toneally one hour before infusion.
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Reserpine (Serpasi^, CIBA pharmaceutical Co,) was dis­
solved in distilled water at pH 2.2 by addition of acetic 
acid. This drug was given to three groups of animals intra­
muscularly at 1.2 5 mg/kg 72 hours prior, 2.5 mg/kg 24 hours 
prior and 2.5 mg/kg 2 weeks prior to infusion in the McN2165 
experiment. In the barium chloride, strophanthin K and aco­
nitine experiments, the rats were injected with 2.5 mg/kg of 
reserpine intramuscularly 24 hours prior to infusion- In the 
aconitine experiment, one group of rats was given 2.5 mg/kg 
of reserpine intraperitoneally 24 hours prior to infusion.
Calculations
The heart rates of the animals were recorded before pre­
treatment to see if the pretreatment had any effect on 
cardiac rhythm. The time required for the arrhythmogenic 
agents to induce ventricular fibrillation was converted to 
dose. The following formula was used to convert the time 
(sec) to dose (mg/kg):
time (sec) x Concentration of drug (mg/ml)
_________X rate of infusion (ml/sec)________
weight (kg)
The total doses were averaged to give a mean dose plus or 
minus the standard deviation.
The doses required to produce these changes were com­
pared for the control and drug-treated groups. Student's 
t-test was used for statistical analysis of the result. The 
5% level of significance was arbitrarily chosen to define
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whether values were or were not significantly different.
The fraction of fibrillating animals was also calculated and 
recorded.
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CHAPTER 3 
RESULTS AND DISCUSSION 
Preliminary Findings
Anesthetized rats were hooked up to the Lead II elec­
trocardiograph for observation. It was found that the dose 
of sodium pentobarbital that was just sufficient to anes­
thetize the animal had little or no suppressant effect on the 
heart. The average heart rate was 420 beats per minute.
There was uniform heart rhythm and no arrhythmias or abnormal 
beats were found in any anesthetized rats.
Kostis and co-worker (1973) showed that alcohol demon­
strated antiarrhythmic properties at high doses and also 
suppressed ventricular tachycardia. The ventricular fibril­
lation threshold was increased as the blood alcohol concen­
tration increased and the threshold value decreased as the 
alcohol level decreased with time. In the present study, 
control solution of 75% alcohol and 25% saline was infused 
into ten of the anesthetized animals. The heart rate did not 
change after infusion of 0.5 ml and a slight decrease in 
heart rate to about 380 beats per minute occurred after 1.5 
ml of infusion. These volumes are above the average volume
15
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(0.3 - 0.4 ml) of infusion of McN2165 used to induce ventri­
cular fibrillation.
The effects of norepinephrine and isoproterenol on 
reserpinized animals was investigated- A dose of 4 yg/kg of 
norepinephrine was the highest dose that could be given with­
out causing any cardiac arrhythmias. The maximum dose of 
isoproterenol was also in the same dosage range.
A dose of 2.5 mg/kg (IM) reserpine was given to the 
animals for the reserpinized experiment. The animals were 
sedated and exhibited some diuretic effects after 24 hours.
The animals given intraperitoneal reserpine also appeared to 
have a lower body temperature.
Animals pretreated with atropine showed a mild increase 
in heart rate which meant the vagal influence was blocked. 
Likewise, animals pretreated with neostigmine showed decreased 
heart rate due to an increased vagal influence.
Animals pretreated with phenoxybenzamine had a higher 
heart rate than the control. This is a common effect of this 
agent. The animals pretreated with pronethalol had a lower 
heart rate due to beta, adrenergic blockade.
Results
Effects of reserpine pretreatment on ventricular fibril­
lation induced by McN216 5 (Table 1 ). The reserpinized animals 
were sedated and their heart rate was depressed from 42 0/min 
to 360/min and 240/min in a dose-related fashion. Pretreat-
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TABLE 1
Effect of reserpine pretreatment on ventricular 
fibrillation induced by McW2165
Treatment
Fibrillation 
threshold (mg/kg)
Fraction
fibrillating
Control 6.6 + 1.0 20/30
Reserpine 1.25 mg/kg 72 hrs 7.2 + 1.9 7/9
Reserpine 2.5 mg/kg 24 hrs 10. 4 ± 3.5* 8/10
Reserpine 2.5 mg/kg 2 wks 8.1 + 1.8* 9/9
Fibrillation threshold is defined as the total dose (mg/kg) 
of the arrhythmogenic agent that was infused into the 
animal to cause ventricular fibrillation.
^Fraction fibrillating is defined as the ratio of the animals 
that demonstrated ventricular fibrillation to the total 
animals used in the experiment.
*significantly different from control (p < 0.01)
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ment with reserpine (.1.25 mg/kg 72 hrs.) showed an in­
significant increase in the fibrillation threshold to 7.2 ± 
1.9 mg/kg. An intramuscular dose of 2.5 mg/kg (.24 hrs. prior) 
of reserpine increased the threshold significnatly to 10.4 ±
3.5 mg/kg (p < 0.01). The same dose given two weeks before 
infusion raised the threshold to 8.1 ± 1.8 mg/kg (p < 0.01) 
which was still significantly different from the control.
MCN2165 was administered by intravenous infusion to 23 
rats. Twenty out of 2 3 animals produced ventricular fibril­
lation after a period of time. The average threshold dose to 
induce ventricular fibrillation was 6.6 ± 1.0 mg/kg. Three 
of the rats never exhibited ventricular fibrillation. Their 
hearts went into tachycardia then slowed to a stop as the 
infusion was continued. The McN2165 induced cardiac arrhyth­
mia went gradually from tachycardia to ventricular flutter 
and terminated with ventricular fibrillation. The fibrilla­
tion lasted about 45 seconds to one minute. After the fi­
brillation the heart exhibited cardiac standstill with occa­
sional beats.
Effects of autonomic drugs on ventricular fibrillation 
induced by McN2165 (Table 2). Immediately after injection of
0.05 mg/kg isoproterenol, the heart rate went up from 420/min 
to 540/min. Isoproterenol decreased the threshold dose from
6.6 ± 1.0 mg/kg to 4.4 ± 0.4 mg/kg (p < 0.01).
After injection of pronethalol, the heart rate decreased 
to about 300/min and then came back to about 380/min after
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TABLE 2
Effect of autonomic drugs on ventricular 
fibrillation induced by McN2165
Treatment
Fibrillation^ 
threshold (mg/kg)
Fraction^
fibrillation
Control 6. 6 + 1.0 20/23
Isoproterenol 0.05 mg/kg 4.4 4* 0.4* 10/10
Pronethalol 2 mg/kg 7.3 + 1.6 9/12
Pronethalol 5 mg/kg 7.5 ± 1.0# 9/15
Norepinephrine 4 pg/kg 7.5 ± 1.2# 9/9
Phenoxybenzamine 1 mg/kg 8.1 ± 1.7* 11/11
Neostigmine 0.1 mg/kg 8.3 2.7# 6/9
Atropine 1 mg/kg 6.4 + 0.8 6/6
b
Fibrillation threshold is defined as the total dose (mg/kg) 
of the arrhythmogenic agent that was infused into the 
animal to cause ventricular fibrillation.
Fraction filbriHating is defined as the ratio of the 
animals that demonstrated ventricular fibrillation to the 
total animals used in the experiment.
*significantly different from control (p < 0.01)
#significantly different from control (0.02 < p < 0,05)
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10 minutes. Pronethalol at a dose of 2 mg/kg increased the 
threshold slightly but not significantly. Five mg/kg of pro­
nethalol increased the fibrillation threshold to 7.5 ± 1.0 
mg/kg (0.02 < p < 0.05).
Phenoxybenzamine 1 mg/kg increased the heart rate to 
500/min. The fibrillation threshold was also increased to
8.1 ± 1.7 mg/kg Cp < 0.01). The increased heart rate may be 
due to reflex vasodilation or potentiation of the effect of 
catecholamines on heart rate. This is a common effect with 
phenoxybenzamine (Stafford, 1963),
A dose of 4 wg/kg of norepinephrine and 0.1 mg/kg of 
neostigmine increased the fibrillation threshold to 7.5 ±
1.2 mg/kg (0.02 < p < 0.05) and 8.3 ± 2.7 mg/kg (0.02 < p < 
0.05) respectively.
There was a slight increase in heart rate after 1 mg/kg 
of atropine but there was no change in the fibrillation 
threshold. The increased heart rate may be due to vagal 
blockage (Goodman and Gilman, 19 70),
Effects of reserpine pretreatment and autonomic drugs 
on ventricular fibrillation induced by McN2165 (Table 3). 
Pretreatment with reserpine (2.5 mg/kg IM, 24 hrs.) and 
norepinephrine (4 yg/kg IV, 20 sec.) before McN2165 infusion 
raised the threshold to 10.5 ± 2.1 mg/kg (p < 0.01) . VJhile 
pretreatment with 2.5 mg/kg of reserpine (IM 24 hrs.) plus 
0.05 mg/kg of isoproteronol (IV, 20 sec.) decreased the 
threshold to 4.5 ± 0.7 mg/kg (p < 0.01), These data imply
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TABLE 3
Effect of reserpine pretreatment and autonomic 
drugs on ventricular fibillation induced by McN2165
Treatment
Fibrillation^ 
threshold (mg/kg)
Fraction^ 
fibrillating
Control 6.6 ± 1.0 20/23
Reserpine 2,5 mg/kg 24 hrs 10.4 ± 3.5* 8/10
Reserpine 2.5 mg/kg 24 hrs 
+ norepinephrine 4 yg/kg 10.5 ± 2.1* 8/11
Reserpine 2.5 mg/kg 24 hrs 
+ isoproterenol 0,05 mg/kg 4.5 ± 0.7* 10/10
Fibrillation threshold is defined as the total dose (mg/kg) 
of the arrhythmogenic agent that was infused into the 
animal to cause ventricular fibrillation.
^Fraction fibriHating is defined as the ratio of the 
animals that demonstrated ventricular fibrillation to the 
total animals used in the experiment.
*significantly different from control (p < 0.01)
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the involvement of the autonomic nervous system in the 
McN2165-induced arrhythmias.
Effects of reserpine pretreatment on ventricular fibril­
lation Induced by various arrhythmogenic agents (Table 4). 
Strophanthin K induced ventricular fibrillation at 25.4 ±
2.4 mg/kg. Initially, the heart rate was decreased. This 
was followed by some disturbances of the QRS complex. Further 
infusion caused ventricular fibrillation and cardiac arrest. 
Pretreatment with 2.5 mg/kg reserpine (IM, 24 hrs.) increased 
the threshold to 33.5 ± 3.5 mg/kg Cp < 0.01).
Barium chloride induced ventricular fibrillation at 21.7 
± 4.0 mg/kg. The heart went through tachycardia for a brief 
period followed by a sudden onset of ventricular fibrilla­
tion. Cardiac standstill occurred in about 30 seconds. Re- 
serpinization raised the threshold dose approximatly 50%.
Aconitine induced ventricular fibrillation at 0.043 ±
0.01 mg/kg. This agent caused ventricular tachycardia and 
ventricular fibrillation within a short period of time. Pre­
treatment with reserpine at a dose of 2.5 mg/kg (IM, 24 hrs.) 
did not change the threshold. The same pretreatment (2.5 mg/ 
kg 2 4 hrs.) given intraperitoneally raised the threshold to 
0.093 ± 0.03 mg/kg (p < 0.01), which is a 110% increase.
Effect of pronethalol pretreatment (5 mg/kg IV, 10 min.) 
on ventricular fibrillation induced by various arrhythmogenic 
agents (Table 5). A dose of 5 mg/kg of pronethalol increased
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TABLE 4
Effect of reserpine on ventricular fibrillation
induced by various arrhythmogenic agents
Treatment
Fibrillation^ 
threshold (mg/kg)
Fraction^ 
fibrillating
Strophanthin K 25. 4 2.4 7/7
Strophanthin K + 
Reserpine 25 mg/kg 24 hrs 33,5 3,5* 7/7
Barium chloride 21. 7 4.0 9/9
Barium chloride + 
Reserpine 2.5 mg/kg 24 hrs 33.7 4.3* 11/11
Aconitine 0.043 0.01 10/10
Aconitine + 
Reserpine 2.5 mg/kg 24 hrs 0.053 0.02 6/6
Aconitine + 
Reserpine 2.5 mg/kg IP 24 hrs 0.093 0.03* 9/9
Fibrillation threshold is defined as the total dose (mg/kg) 
of the arrhythmogenic agent that was infused into the 
animal to cause ventricular fibrillation.
^Fraction fibrillating is defined as the ratio of the animals 
that demonstrated ventricular fibrillation to the total 
animals used in the experiment.
*significantly different from control (p < 0.01)
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TABLE 5
Effect of pronethalol on ventricular fibrillation
induced by various arrhythmogenic agents
Treatment
Fibrillation^ 
threshold (mg/kg)
Fraction^ 
fibrillating
Strophanthin K 25. 4 ± 2.5 7/7
Strophanthin K -f 
Proethalol 5 mg/kg 36.4 ± 6.4* 4/10
Barium chloride 21.7 + 4.0 9/9
Barium chloride + 
Pronethalol 5 mg/kg 38.5 ± 8.0* 8/8
Aconitine 0. 042 ± 0. 01 10/10
Aconitine + 
Pronethalol 5 mg/kg 0. 055 ± 0.01# 7/7
Fibrillation threshold is defined as the total dose (mg/kg) 
of the arrhythmogenic agent that was infused into the animal 
to casue ventricular fibrillation.
^Fraction fibrillating is defined as the ratio of the animals 
that demonstrated ventricular fibrillation to the total 
animals used in the experiment.
*significantly different from control (p < O.Ol) 
^significantly different from control (.0.02 < p < 0.05)
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the fibrillation threshold significantly for all three arrhy­
thmogenic agents. The threshold dose for strophanthin K, 
barium chloride and aconitine after pretreatment with 5 mg/ 
kg of pronethalol (IV, 10 min.) were 36.4 ± 6.4 mg/kg (p < 
0.01), 35.5 ± 8.0 mg/kg (p < 0.01) and 0.055 ± 0.01 mg/kg 
(.0.02 < p < 0.05) respectively.
Effect of isoproterenol pretreatment (0,05 mg/kg IV, 20 
sec.) on ventricular fibrillation induced by various arrhyth­
mogenic agents (Table 6). Isoproterenol decreased the fibril­
lation threshold of strophanthin K to 15.7 ± 4.2 mg/kg (p < 
0.01) and increased the fibrillation threshold of barium 
chloride to 31.9 ± 4.3 mg/kg (p < 0.01). The fibrillation 
threshold of aconitine was not significantly altered by iso­
proterenol pretreatment.
Effect of pronethalol 5 mg/kg on cessation of ventricu­
lar fibrillation (Table 7). A intravenous dose of 5 mg/kg 
of pronethalol, given at the onset of ventricular fibrillation 
induced by McN216 5, restored the normal rhythm in 11 out of 
11 animals. None of the eight animals stopped ventricular 
fibrillation after induction by barium chloride. Also, no 
aconitine-induced fibrillation could be halted with 5 mg/kg 
of pronethalol.
Discussion
The production of ventricular arrhythmias by McN2165 in 
anesthetized dogs was first published by Pruss (1969).
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TABLE 6
Effect of isoproterenol on ventricular fibrillation
induced by various arrhythmogenic agents
Treatment
Fibrillation^ 
threshold (mg/kg)
Fraction^ 
fibrillating
Strophanthin K 25.4 2.5 7/7
Strophanthin K + 
Isoproterenol 0.05 mg/kg 15,7 4.2* 3/8
Barium chloride 21,7 4.0 9/9
Barium chloride + 
Isoproterenol 0.05 mg/kg 31. 9 4.3* 8/8
Aconitine 0.042 0,01 10/10
Aconitine + 
Isoproterenol 0.05 mg/kg 0.051 0.01 8/8
Fibrillation threshold is defined as the total dose (mg/kg) 
of the arrhythmogenic agent that was infused into the animal 
to cause ventricular fibrillation.
^Fraction fibrillating is defined as the ratio of the animals 
that demonstrated ventricular fibrillation to the total 
animals used in the experiment.
*significantly different from control (p < 0.01)
Reproduced with permission of the copyright owner. Further reproduction prohibited without permission.
27
TABLE 7
Effect of 5 mg/kg of pronethalol on recovery 
from ventricular fibrillation
Treatment Fraction Recovery^
MCN2165 0/20
MCN2165 + Pronethalol 11/11
Barium chloride 0/9
Barium chloride + Pronethalol 0/8
Aconitine 0/10
Aconitine + Pronethalol 0/8
^Animals were given sufficient arrhythmogenic agent 
to induce fibrillation. At this point, 5 mg/kg of 
pronethalol was given. Fraction recovery is the 
ratio of those who returned to normal rhythm to the 
total number that fibrillated
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Further studies by Eyer and Johnson (1977) showed that MCN2165 
slowed the heart rate and increased the cyclic AMP level in 
isolated fetal rat heart preparations. The same study also 
found that McN216 5 could not induce tachycardia or ventricu­
lar fibrillation in such a preparation. One possible explan­
ation could be that the fetal rat did not have a well devel­
oped sympathetic nervous system. Since sympathetic activity 
might be involved, reserpine was used to determine the rela­
tionship between catecholamines and fibrillation. This drug 
has a biphasic effect on the heart rate (Krayer, et al, 1958). 
After reserpine administration, the heart rate increased for 
the first few hours due to the release of catecholamines, 
then decreased for about two to three weeks due to the deple­
tion of these amines. About four weeks was required for the 
animals to return to normal levels of catecholamines. Direct 
cardiac effects of reserpine include depression of excitable 
membranes (Innes, et al, 1958). The ability of reserpine to 
increase the fibrillation threshold was most likely due to 
the depletion of catecholamines. In this study the antifi- 
brillatory action persisted for more than four weeks. The 
possibility of a direct membrane effect of reserpine can be 
ruled out because the antifibrillatory action persisted long 
after the drug had been excreted. A 1.2 5 mg/kg dose of re­
serpine caused less sedation than a dose of 2.5 mg/kg and did 
not significantly raise the fibrillation threshold (Table 1). 
This was probably due to less depletion of the catecholamines.
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The 2.5 mg/kg dose (24 hrs prior) was a sufficient dose to 
deplete all the catecholamines without much membrane effect 
(Boyajy, et al, 1965). Therefore, the increase in ventricu­
lar fibrillation threshold by reserpine implied that catecho­
lamines might play a role in the fibrillatory action of 
MCN2165.
A dose of 0.1 mg/kg of neostigmine increased the fibril­
lation threshold significantly while atropine did not change 
the threshold. Large doses of acetylcholine are known to 
convert the atrial flutter induced by aconitine into fibril­
lation through the development of multiple re-entries in the 
atria (Sharma, 1963; Burn, et a l , 1956), It was also found 
that acetylcholine or carbachol was able to inhibit the syn­
thesis of cyclic AMP by 20 to 30% in dog cardiac muscle 
preparation (Murad, et al, 1961). This increase in threshold 
by neostigmine can be explained if McN2165-induced fibrilla­
tion requires increased cyclic AMP levels, McN2165 has been 
shown to elevate cyclic AMP levels (Eyer and Johnson, 1977). 
The lack of effect of atropine on McN216 5 was in agreement 
with Pruss' (1969) finding.
Blockade of the alpha and beta receptors by 1 mg/kg of 
phenoxybenzamine and 2 mg/kg or 5 mg/kg of pronethalol in­
creased the fibrillation threshold. This implied that both 
alpha and beta receptors were involved in the induction of 
fibrillation. Only 9 out of 15 rats pretreated with pro­
nethalol fibrillated. The other six animals demonstrated no
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arrhythmias whatsoever. All the animals pretreated with 
pnehoxybenzamine underwent ventricular fibrillation. This 
indicated the involvement of beta receptors in the arrhyth­
mias induced by McN2165, although the agent might have acted 
on both alpha and beta receptors. Pronethalol itself had 
some transient cardiac depressant actions similar to quinidine 
(Sekiya, et al, 1963). It is also known that beta receptor 
blockers are effective in preventing the beta-stimulated 
elevation of cyclic AMP levels in the cardiac tissue (Dobson, 
et a 1 , 1973) .
The norepinephrine data was difficult to explain because 
it increased the fibrillation threshold (Table 2). This 
could be due to the biphasic effects catecholamines have on 
the fibrillation threshold- In low doses, catecholamines 
increased the ventricular fibrillation threshold and in high 
doses it lowered the threshold (MacConaill, et a l , 1967, 
Hoffman, et al, 1955). Evidently the high dose that lowered 
the threshold was not attained. Another explanation could be 
that norepinephrine acted more on the alpha receptors than 
the beta receptors. Alpha receptor activation may be related 
to decrease in the intracellular level of cyclic AMP (Turtle, 
et al, 1967). Isoproterenol, a potent beta agonist, de­
creased the fibrillation threshold (Table 2). Beta agonists 
also effectively increase cyclic AMP levels in the heart 
(Sutherland, et al, 1960), In reserpinized animals, isopro­
terenol was capable of lowering the fibrillation threshold.
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This was not possible with norepinephrine. This was further 
evidence that beta receptors are more involved than alpha 
receptors in the arrhythmogenesis produced by McN2165.
McN2165 has been shown to slow conduction of the action 
potential in the heart, block the A.V. node (_Pruss, 1969),
and increase the cyclic AMP level (Eyer and Johnson, 1977).
High cyclic AMP levels have been implicated in ventricular 
fibrillation (Opie, et al, 1976), Neostigmine and proneth­
alol, agents that lower the cyclic AMP levels in the heart, 
increased the McN2165 fibrillation threshold. Isoproterenol 
increased the level of cyclic AMP and decreased this thresh­
old. Only isoroterenol could decrease the fibrillation 
threshold of reserpinized animals to the control value. Thus,
elevation of cyclic AMP levels in the heart are implicated in
the fibrillatory response to McN2165.
Of the three arrhythmogenic agents compared with McN2165, 
only strophanthin K and barium chloride elevated the fibril­
lation threshold in reserpinized animals (2.5 mg/kg 24 hrs 
prior to treatment). Tatsuno (1976) also found that sympa­
thetic activities were involved in the production of arrhy­
thmias by strophanthin K, Blockage of strophanthin K- 
induced arrhythmias by a i>e ta-adrenergic antagonist is well 
documented (Somani and Lum, 1965; Sekiya and Vaughan Williams, 
1963). Lowered fibrillation threshold following isoproterenol 
pretreatment further demonstrated that beta sympathetic acti­
vities are involved in the induction of ventricular fibrilla­
tion .
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Pretreatment with reserpine, pronethalol and isoproter­
enol all increased the fibrillation threshold of barium 
chloride. Barium chloride causes arrhythmias by direct myo­
cardial irritation. It resembles calcium in its ability to 
produce extrasystoles, increase cardiac automaticity and in­
duce ventricular fibrillation (McMillan, et a l , 1928). It 
is possible that the slight membrane effect of reserpine or 
pronethalol was able to suppress the irritation of barium 
chloride, so that it took more barium chloride to irritate 
the myocardial muscle, while isoproterenol increased the 
heart rate and force which made it more difficult for barium 
chloride to disturb the increased rhythm.
A dose of 2.5 mg/kg of reserpine (IM 24 hrs. prior) did 
not alter the fibrillation threshold of aconitine. The same 
dose given intraperitoneally increased the threshold signi­
ficantly. This showed that either catecholamines may not be 
involved in the arrhythmia or only a low level of catechol­
amines is necessary for aconitine-induced fibrillation. The 
increase in threshold might be due to the enhanced membrane 
activity of reserpine because intraperitonea1 injection pro­
duced higher blood levels of the drug (Goldstein, 1974). 
Another explanation could be that a minute amount of cate­
cholamines is required for aconitine to induce fibrillation. 
With a higher blood concentration of reserpine, there will be 
a greater depletion of catecholamines, which could increase 
the amount of aconitine required to induce fibrillation.
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Isoproterenol pretreatment did not change that threshold.
This is further evidence that catecholamines were not in­
volved in the arrhythmias or that only small amounts are 
needed. Pronethalol increased the aconitine fibrillation 
threshold, contrary to the data of Tatsuno, et ai, (1976),
The quinidine-like or local anesthetic effect is unlikely 
because administration of pronethalol failed to suspend the 
fibrillation induced by aconitine. Pronethalol could have 
some other unknown effects on suppressions of ectopic activ­
ities of aconitine.
A dose of 5 mg/kg of pronethalol was injected intraven­
ously during the ventricular fibrillation induced by McN2165, 
barium chloride, and aconitine (Table 7). Only McN2165- 
induced fibrillation was suspended. These hearts returned 
to normal rhythm. Barium chloride-and aconitine-induced fi­
brillation were not suspended by pronethalol. The fibrilla­
tion continued until cardiac arrest occurred.
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SUMMARY
McN2165 is an arrhythmogenic agent that produces ven­
tricular fibrillation in rats. In order to investigate the 
mechanism of action of this agent, autonomic agonists and 
antagonists were employed to modify the physiological states 
of the rat heart. The influence of these autonomic drugs on 
McN2165-induced ventricular fibrillation was compared with 
other arrhythmogenic agents. Pretreatment with either 
reserpine, pronethalol, norepinephrine, phenoxybenzamine or 
neostigmine increased the fibrillation threshold of McN2165. 
Atropine pretreatment did not change the fibrillation 
threshold, while isoproterenol pretreatment decreased the 
fibrillation threshold. Norepinephrine failed to decrease 
the fibrillation threshold of the reserpinized animals. Iso­
proterenol was the only autonomic drug that could decrease 
the McN2165 fibrillation threshold in the reserpinized 
animals. When fibrillation was induced by McN2165, adminis­
tration of pronethalol restored normal cardiac rhythm.
The fibrillation threshold of strophenthin K was in­
creased by either reserpine or pronethalol pretreatment. 
Isoproterenol was able to lower the fibrillation threshold
34
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but pronethalol was not able to stop the fibrillation induced 
by the agent.
Pretreatment with either reserpine, pronethalol or 
isoproterenol raised the fibrillation threshold of barium 
chloride, Pronethalol was not able to stop the fibrillation 
induced by barium chloride.
Intraperitoneal injection of reserpine and pretreatment 
with pronethalol increased the fibrillation threshold of 
aconitine. Isoproterenol did not change the fibrillation 
threshold of aconitine. Aconitine-induced ventricular fibril­
lation could not be halted by pronethalol.
These data demonstrate a stronger involvement of the 
beta receptor in the action of McN2165 than for the other 
arrhythmogenic agents studied. Although these agents re­
sembled MCN2165 in some respects, certain differences in 
their mechanism of action have been demonstrated-
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